Hainan Huluwa Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has an Asset Resilience Ratio of 0.95% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Hainan Huluwa Pharmaceutical Group Co Lt to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Hainan Huluwa Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Hainan Huluwa Pharmaceutical Group Co Lt (605199) total assets.
Liquid Assets Composition Over Time
This chart breaks down Hainan Huluwa Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 605199 total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥14.00 Million | 0.95% |
| Total Liquid Assets | CN¥14.00 Million | 0.95% |
Asset Resilience Insights
- Limited Liquidity: Hainan Huluwa Pharmaceutical Group Co Ltd maintains only 0.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Huluwa Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hainan Huluwa Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd (None–None)
The table below shows the annual Asset Resilience Ratio data for Hainan Huluwa Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more